NCT07209384尚未招募2 期
CLINICAL EFFICACY OF TRANSARTERIAL CHEMOEMBOLIZATION IN ELDERLY PATIENTS WITH ADVANCED UNRESECTABLE COLORECTAL CANCER
Junpeng Wang0 个研究点目标入组 50 人开始时间: 2025年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
- 主要终点
- Objective Response Rate；Disease Control Rate
研究概览
简要总结
We plan to conduct a prospective, two-arm, open-label phase Ⅱ study to evaluate whether transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab significantly improves the efficacy and safety compared with systemic FOLFOX therapy plus/minus cetuximab/bevacizumab in elderly patients with advanced unresectable colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 65 years, gender not restricted Pathologically confirmed advanced colorectal cancer without the opportunity for curative surgery Karnofsky Performance Status (KPS) score ≥ 60, with an estimated survival time ≥ 3 months At least 1 measurable colorectal lesion No prior systemic chemotherapy, or a minimum interval of 6 months between the last chemotherapy and study enrollment Voluntary signing of the informed consent form
排除标准
- •Concomitant other malignant tumors Presence of gastrointestinal perforation Severe cardiovascular and cerebrovascular diseases Patients with hypersensitivity to study drugs or psychiatric disorders
研究组 & 干预措施
transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab
Experimental
干预措施: Transarterial chemoembolization (Procedure)
结局指标
主要结局
Objective Response Rate；Disease Control Rate
时间窗: 24 weeks
次要结局
未报告次要终点
研究者
Junpeng Wang
Chief physician
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
相似试验
撤回
2 期
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerCancer of the Bile DuctGallbladder CancerNCT00386516Galectin Therapeutics Inc.
招募中
2 期
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsDLBCLNCT06569485Sun Yat-sen University38
进行中（未招募）
2 期
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLPCNSLSecondary Central Nervous System LymphomaNCT04438044Beijing InnoCare Pharma Tech Co., Ltd.61
已完成
2 期
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaWaldenstrom's Macroglobulinemia RecurrentWaldenstrom's Macroglobulinemia RefractoryNCT04440059Beijing InnoCare Pharma Tech Co., Ltd.47
已完成
2 期
Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The EsophagusAdenocarcinomaNCT00259987GlaxoSmithKline24